Is SARS-CoV-2 an oncogenic virus? - 13/10/22
Doi : 10.1016/j.jinf.2022.08.005
Alberto Gómez-Carballa a, b, d 
, Federico Martinón-Torres a, b, c , Antonio Salas a, b, d, ⁎
, Federico Martinón-Torres a, b, c , Antonio Salas a, b, d, ⁎ a Genetics, Vaccines and Infections Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain
c Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
d Unidade de Xenética, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, Spain
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Npa2 and Npa3 SARS-CoV-2 protein have the ability to hijack and degrade p53. |
• | Gene expression of p53 is downregulated in blood of COVID-19 patients. |
• | Downregulation of p53 persists at least 24 weeks after infection in long COVID-19 patients. |
• | Long-term reduction of p53 could have impact on carcinogenesis. |
Keywords : COVID-19, SARS-CoV-2, Cancer, TP53
Plan
© 2022
Publié par Elsevier Masson SAS.
Vol 85 - N° 5
P. 573-607 - novembre 2022 Retour au numéro
Article précédent
- Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak
- V Mazzotta, A Mondi, F Carletti, F Baldini, R Santoro, S Meschi, M Moccione, S Gebremeskel Teklè, C Minosse, M Camici, S Vita, G Matusali, E Nicastri, E Girardi, F Maggi, F Vaia, A Antinori, C Pinnetti
- Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data
- Matteo Bassetti, Valentina Zuccaro, Erika Asperges, Luigia Scudeller, Daniele Roberto Giacobbe, FUNDICU investigators (collaborators), M. Akova, A. Alastruey-Izquierdo, S. Arikan-Akdagli, E. Azoulay, S. Blot, A. Cortegiani, O.A. Cornely, C. Grecchi, C. Lass-Flörl, P. Koehler, M. Cuenca-Estrella, D.W. de Lange, F.G. De Rosa, J.J. De Waele, G. Dimopoulos, J. Garnacho-Montero, M. Hoenigl, S.S. Kanj, F. Lamoth, J. Maertens, I. Martin-Loeches, P. Muñoz, B.J. Kullberg, C. Agvald-Ohman, G. Poulakou, C. Rebuffi, J. Rello, M. Sanguinetti, F.S. Taccone, J-F. Timsit, A. Torres, J.A. Vazquez, J. Wauters, T. Calandra, S. Tejada, I. Karaiskos, M. Peghin, A. Vena, K.L. Mortensen, C. Lebihan, T. Mercier
Bienvenue sur EM-consulte, la référence des professionnels de santé.